1.40
price up icon1.45%   0.02
after-market 시간 외 거래: 1.30 -0.10 -7.14%
loading
전일 마감가:
$1.38
열려 있는:
$1.37
하루 거래량:
34,016
Relative Volume:
0.27
시가총액:
$42.14M
수익:
-
순이익/손실:
$-60.70M
주가수익비율:
-0.6863
EPS:
-2.04
순현금흐름:
$-61.05M
1주 성능:
-7.89%
1개월 성능:
+22.81%
6개월 성능:
+33.33%
1년 성능:
-58.82%
1일 변동 폭
Value
$1.37
$1.42
1주일 범위
Value
$1.28
$1.50
52주 변동 폭
Value
$0.87
$3.535

An 2 Therapeutics Inc Stock (ANTX) Company Profile

Name
명칭
An 2 Therapeutics Inc
Name
전화
(650) 331-9090
Name
주소
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Name
직원
36
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
ANTX's Discussions on Twitter

ANTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ANTX
An 2 Therapeutics Inc
1.40 42.14M 0 -60.70M -61.05M -2.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-08-09 다운그레이드 Evercore ISI In-line → Underperform
2024-08-09 다운그레이드 Leerink Partners Outperform → Market Perform
2024-07-03 업그레이드 Leerink Partners Market Perform → Outperform
2024-04-02 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2024-02-13 다운그레이드 Leerink Partners Outperform → Market Perform
2024-02-12 다운그레이드 Evercore ISI Outperform → In-line
2024-02-12 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2024-02-12 다운그레이드 Oppenheimer Outperform → Perform
2024-01-04 개시 JMP Securities Mkt Outperform
2022-07-18 재개 Oppenheimer Outperform
모두보기

An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스

pulisher
06:00 AM

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - Quantisnow

06:00 AM
pulisher
Mar 31, 2025

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - Yahoo Finance

Mar 31, 2025
pulisher
Mar 26, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Quantisnow

Mar 26, 2025
pulisher
Mar 25, 2025

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - The Manila Times

Mar 25, 2025
pulisher
Mar 20, 2025

Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq

Mar 20, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - Yahoo Finance

Mar 17, 2025
pulisher
Mar 16, 2025

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - Yahoo Finance

Mar 16, 2025
pulisher
Mar 12, 2025

Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire

Mar 12, 2025
pulisher
Mar 12, 2025

Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - Yahoo Finance

Mar 12, 2025
pulisher
Mar 10, 2025

Sun Pharma Shares Gain 2% on Plans to Acquire Checkpoint Therapeutics - Equitypandit

Mar 10, 2025
pulisher
Mar 10, 2025

Latest News | Sun Pharma Shares Rise over 2 Pc as Company to Acquire Checkpoint Therapeutics - LatestLY

Mar 10, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

Black Diamond Therapeutics Reports Fourth Quarter and Full - GlobeNewswire

Mar 06, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire

Mar 05, 2025
pulisher
Mar 04, 2025

HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open - Yahoo Finance

Mar 04, 2025
pulisher
Mar 03, 2025

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - BioSpace

Mar 03, 2025
pulisher
Mar 02, 2025

Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Feb 28, 2025

Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial resultsICYMI - Proactive Investors USA

Feb 28, 2025
pulisher
Feb 27, 2025

Silver Bullet Therapeutics Announces Podcast Scheduled to Air on March 2, 2025 - Yahoo Finance

Feb 27, 2025
pulisher
Feb 26, 2025

Cognition Therapeutics Successfully Passes Pre-defined - GlobeNewswire

Feb 26, 2025
pulisher
Feb 25, 2025

Medicenna Therapeutics Corp. - Baystreet.ca

Feb 25, 2025
pulisher
Feb 25, 2025

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - GlobeNewswire

Feb 25, 2025
pulisher
Feb 24, 2025

Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients - Yahoo Finance

Feb 24, 2025
pulisher
Feb 22, 2025

Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance

Feb 22, 2025
pulisher
Feb 20, 2025

Cardiol Therapeutics Inc. - Baystreet.ca

Feb 20, 2025
pulisher
Feb 16, 2025

2025-02-16 | APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit | NDAQ:APLT | Press Release - Stockhouse Publishing

Feb 16, 2025
pulisher
Feb 12, 2025

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting - Yahoo Finance

Feb 12, 2025
pulisher
Feb 12, 2025

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire

Feb 12, 2025
pulisher
Feb 11, 2025

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewswire

Feb 11, 2025
pulisher
Feb 08, 2025

Conduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase II - Yahoo Finance

Feb 08, 2025
pulisher
Feb 07, 2025

AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025 - Yahoo Finance

Feb 07, 2025
pulisher
Feb 07, 2025

Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire

Feb 07, 2025
pulisher
Feb 07, 2025

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - Yahoo Finance

Feb 07, 2025
pulisher
Feb 07, 2025

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD (NASDAQ:COYA) - Seeking Alpha

Feb 07, 2025
pulisher
Feb 06, 2025

Allarity Therapeutics Announces Expansion of Phase 2 - GlobeNewswire

Feb 06, 2025
pulisher
Feb 06, 2025

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Breakthrough Ovarian Cancer Drug Shows 14-Month Durability: Allarity Advances Clinical Trial - Stock Titan

Feb 06, 2025
pulisher
Feb 05, 2025

Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring - Seeking Alpha

Feb 05, 2025
pulisher
Feb 04, 2025

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PR Newswire

Feb 04, 2025
pulisher
Feb 03, 2025

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis - Yahoo Finance

Feb 03, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic Announces Positive Interim Data from - GlobeNewswire

Jan 30, 2025
pulisher
Jan 29, 2025

CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Major Setback: CARGO's Cancer Treatment Shows Alarming Safety Issues, Forces Company Restructure - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance

Jan 29, 2025
pulisher
Jan 29, 2025

Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News

Jan 29, 2025
pulisher
Jan 29, 2025

APLT Lead Plaintiff Deadline ApproachingContact Robbins LLP for Information About the Pending Class Action Against Applied Therapeutics, Inc. - The Malaysian Reserve

Jan 29, 2025

An 2 Therapeutics Inc (ANTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
자본화:     |  볼륨(24시간):